Beraprost modified release - Lung Biotechnology/Toray Industries

Drug Profile

Beraprost modified release - Lung Biotechnology/Toray Industries

Alternative Names: Beraprost modified release lung rx; Beraprost MR - Lung Biotechnology/Toray Industries; Beraprost sodium modified release; Beraprost sodium MR; BPS-MR

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Toray
  • Developer Lung Biotechnology
  • Class 3-ring heterocyclic compounds; Alkynes; Antiplatelets; Benzofurans; Butyric acids; Cyclopentanes; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pulmonary arterial hypertension

Most Recent Events

  • 30 Nov 2013 Lung RX completes a phase II extension trial in Pulmonary Arterial Hypertension in USA, Belgium and Ireland (NCT00792571)
  • 30 Dec 2011 Lung RX completes a phase II extension trial in Pulmonary Arterial Hypertension in USA, Belgium, Ireland, Czech Republic, Romania and Germany (PO) (NCT00990314)
  • 30 Dec 2011 Lung RX completes a phase II trial in Pulmonary Arterial Hypertension in USA, Belgium, Ireland, Czech Republic, Romania and Germany (PO) (NCT00989963)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top